Exciting to see the innovative research coming out of the pipeline! 💡 The novel approaches being explored could have a significant impact on patient care. What specific challenges do you think these new strategies will address in the treatment of hematologic conditions?

Exciting to see Merck expanding its hematology pipeline at #ASH25. Blood cancers demand approaches that are both innovative and economically viable, cause breakthroughs only matter if patients can access them. Novel designs, whether in therapeutics or delivery chassis, must balance scientific ambition with affordability. Sustained investment and transparent stewardship will be the difference between promising data and real‑world impact.

Impressive to see the breadth of research Merck is bringing to ASH25. Important work.

Good Work Everyone 💪❤️

Exciting progress!

Just wow. T-cell redirection, epigenetic modulation, next-wave BTK inhibition, and a ROR1 ADC. Four very different angles on the same core challenge — finding cleaner, more durable ways to outsmart malignant cells.

“Impressive advancement in hematology research. Excited to see Merck driving innovation for better patient outcomes.”